What it is
Somatic evolution in ageing tissues underlies many cancers, but the rules governing pre-cancerous evolution are still poorly quantified. The authors used a unique collection of serial blood samples, drawn annually for up to a decade and beginning as early as 15 years before diagnosis of acute myeloid leukaemia (AML), from women in the UK Collaborative Trial of Ovarian Cancer Screening: 47 women who went on to develop AML and 46 age-matched controls who stayed cancer-free. Deep duplex sequencing combined with evolutionary theory let them estimate when the key driver mutations were acquired and how strongly each made its clone grow. The first driver mutations are typically acquired in the first few decades of life, while the blood is still highly polyclonal, and those early clones grow slowly; they then acquire further driver mutations conferring selective advantages up to 100-fold larger than the early drivers. These faster-growing multi-driver clones can cause complete somatic sweeps of the blood decades before diagnosis, a feature strongly associated with future AML.
Why it matters
The first driver mutations on the path to AML typically arrive in the first decades of life, so its path is under way, and traceable in blood, long before diagnosis. By the model's estimates, two-thirds of the cases had acquired their first driver mutation by age 20, and those first clones grew by only about 10% to 30% a year; the full text reports no selective or completed sweeps in any control. The authors conclude that the clonal dynamics of blood are consistent with a remarkably simple set of evolutionary rules that balance chance and determinism.
Underlined numbers link to their source. Every metric and quoted figure is listed under Sources and data below.
Filed underAcute Myeloid Leukemia Research, Cancer Genomics and Diagnostics, Evolution and Genetic Dynamics